Physician profile
Victor E Salter
NPI 1851398838
$11,640.41
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,903 · 2020: $2,299 · 2021: $3,108 · 2022: $3,220 · 2023: $87.21 · 2024: $22.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,851.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,770.65 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,348.50 | 2019-2024 | Ofev |
| Grifols USA, LLC | $916.18 | 2019-2022 | |
| Insmed, INC. | $912.25 | 2019-2022 | |
| United Therapeutics Corporation | $837.60 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $740.63 | 2019-2023 | Uptravi |
| Genentech USA, INC. | $555.15 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $315.71 | 2019-2021 | |
| Electromed, INC. | $261.64 | 2019-2022 | |
| Gilead Sciences, INC. | $250.60 | 2019-2022 | |
| Advanced Respiratory, INC | $214.42 | 2019-2021 | |
| Genzyme Corporation | $207.84 | 2021-2022 | |
| Mylan Specialty L.P. | $174.92 | 2019-2022 | |
| Csl Behring | $140.34 | 2020-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $123.48 | 2019-2023 | |
| Baxter Healthcare | $99.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.89 | 2021-2022 | |
| Allergan, INC. | $97.58 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $85.94 | 2019 | |
| Inogen, INC. | $60.72 | 2022 | |
| Mallinckrodt Hospital Products INC. | $56.54 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $56.44 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $48.58 | 2019-2020 | |
| Circassia INC. | $45.67 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $43.69 | 2021 | |
| Janssen Pharmaceuticals, INC | $41.49 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $39.77 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.30 | 2021-2022 | |
| Amgen INC. | $39.03 | 2021-2022 | |
| Shire North American Group INC | $29.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.11 | 2019-2022 | |
| Harmony Biosciences LLC | $26.31 | 2022 | |
| Portola Pharmaceuticals, LLC | $19.12 | 2019 | |
| Nabriva Therapeutics, Plc | $16.94 | 2021 | |
| Hospira, INC. | $16.66 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.88 | 2019 | |
| Shionogi INC | $14.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Salter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.